Moreover, in cancer development, their functional crosstalk has been reported with EGFR activating MET or, conversely, with MET expression regulating EGFR tyrosine phosphorylation and cell growth, e.g., in the presence of gefitinib (EGFR inhibitor) in SUM229 breast cancer cells [9]. This evidence concerns the gene EGFR and breast cancer.